August 29, 2024 07:14 AM EDT

BioMarin lays off 225 employees as it cuts spending on gene therapy rollout

Amber Tong

BioMarin’s decision to scale back its gene therapy ambitions will result in about 225 employees losing their jobs, the biotech disclosed late Wednesday.

The layoffs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioMarin lays off 225 employees as it cuts spending on gene therapy rollout

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Post-Hoc: Big promises built Moderna. They might also be its undoing

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

Corrected: Roche’s Tecentriq scores first US approval for subcutaneous PD-L1

Bio­Marin lays off 225 em­ploy­ees as it cuts spend­ing on gene ther­a­py roll­out

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

BioMarin lays off 225 employees as it cuts spending on gene therapy rollout